3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
11
Endocrine
11
Thoracic
4
Gynecologic
4
Gastrointestinal
2
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
541
Precursor Cell Lymphoblastic Leukemia-Lymphoma
310
Hematologic Neoplasms
264
Leukemia
179
Myelodysplastic Syndromes
170
Leukemia, Lymphocytic, Chronic, B-Cell
168
Lymphoma
101
Lymphoma, Non-Hodgkin
94
Recurrence
84
Neoplasms
83
Multiple Myeloma
82
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
72
Leukemia, Myelomonocytic, Chronic
61
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
58
Burkitt Lymphoma
54
Leukemia, Biphenotypic, Acute
48
Myeloproliferative Disorders
45
Lymphoma, Follicular
43
Lymphoma, Mantle-Cell
42
Lymphoma, Large B-Cell, Diffuse
42
Hodgkin Disease
34
Lymphoma, B-Cell
32
Lymphoma, B-Cell, Marginal Zone
30
Leukemia, B-Cell
30
Anemia, Refractory, with Excess of Blasts
30
Primary Myelofibrosis
28
Leukemia, Plasma Cell
23
Waldenstrom Macroglobulinemia
22
Neoplasm, Residual
21
Leukemia, Myeloid, Chronic-Phase
21
Interventions
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Thyroid Carcinoma, Anaplastic
×
Other hematologic neoplasm
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled